In the case of UCB, Inc. et al. v. Mylan Technologies Inc., partner and co-chair of the Intellectual Property Department Deepro Mukerjee and Intellectual Property partners Lance Soderstrom and Jitty Malik successfully represented Vermont-based Mylan Technologies Inc., after the global generic and specialty pharmaceutical company was sued by UCB Inc., a global biopharmaceutical company claiming that Mylan infringed on UCB's patent of its Neupro drug to treat Parkinson's disease. In June, US District Judge Christina Reiss in Delaware issued a final judgement that ruled in Mylan's favor, invalidating UCB's patent of the drug, avoiding a bench trial that was scheduled for mid-July.
Judge Reiss' final decision comes after Third Circuit Judge Kent A. Jordan had invalidated one of two patents asserted against Mylan in April, which UCB has said it will appeal to the Federal Circuit. Both Mylan and UCB agreed to adopt Judge Jordan's final judgement as it relates to one of the patents. For the second patent, both parties agreed to dismiss the infringement and validity claims.